Caricamento...
Empagliflozin/linagliptin single‐tablet combination: first‐in‐class treatment option
BACKGROUND: The availability of a dual sodium glucose co‐transporter 2/dipeptidyl peptidase‐4 inhibitor combination in a single‐tablet combination (STC) represents a new therapeutic option for patients with type 2 diabetes. Empagliflozin/linagliptin STC has been recently approved by the US Food and...
Salvato in:
| Pubblicato in: | Int J Clin Pract |
|---|---|
| Autore principale: | |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
John Wiley and Sons Inc.
2015
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5049636/ https://ncbi.nlm.nih.gov/pubmed/26303997 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/ijcp.12720 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|